Compare Abeona Therapeutics Inc (ABEO) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax COIN Option Income Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while YieldMax COIN Option Income Strategy ETF trades at $18.18. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | CONY | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.45 | $76.50 |
52-Week Low | $4.17 | $17.80 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
CONY trades at $18.54, up 4.16% today, with a bearish technical signal from moving averages but oversold RSI levels. The ETF shows no fundamental valuation ratios available, and recent news highlights significant shareholder losses despite high distribution yields. Weekly dividends are consistently announced, but underlying performance concerns persist.
Outlook remains cautious due to bearish technicals and negative media sentiment emphasizing value erosion. Risks include reliance on options income strategy and Coinbase volatility. Analyst coverage suggests skepticism, with no bullish catalysts evident near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
